I INTRODUCTION
The system of radiological protection recommended by the International Commission on Radiological Protection (ICRP) forms a base of laws related to radiological protection in many countries worldwide, including Japan. Many countries adopted Publication 60 (Publ. 60), 1) the 1990 recommendation of ICRP, into their regulatory systems. In December 2007, 17 years from 1990, ICRP released Publication 103 (Publ. 103), 2) which contains new recommendations based on new findings obtained since 1990. The system of radiological protection recommended by ICRP is based on three principles: justification, optimization, and dose limit. There is no difference between Publ. 60 and Publ. 103 in terms of the three principles. In addition, dose limits are separately speci ed for workers and members of the public. In Publ. 103, the values and rationale for deriving the dose limit in Publ. 60 were used without modi cations. The rationale for deriving the dose limit for members of the public (1 mSv/y) is explained in detail in paragraph 191 of the main text and annex C of Publ. 60. The rationale is explained using 1) the risk-based approach (for example, the annual fatality probability does not exceed 10 -4 until 70 years old even if exposed to 1 mSv/y continuously from 0 years old) and 2) natural background radiation-based approach, which is based on the dose of natural background radiation.
ICRP not only perceives risks associated with cancer and other heritable diseases as risks leading to death due to these diseases, but also adopts a concept on detriment by appropriately taking into consideration the effects associated with nonfatal cancers. ICRP proposed the following method for calculating risk coef cient. The risk coef cient calculated by summing the detriments calculated for all types of cancer (depending on the affected tissue or organ) is derived by considering the following factors: death, relative life lost for fatal cancers and life impairment for nonfatal cancer, which are expected to occur because of these diseases. Thus-obtained detriment-adjusted risk coefficients generally differ between genders and among age groups. ICRP published genderaveraged and age-group-averaged nominal risk coefficients in both Publ. 60 and Publ. 103. On the basis of these values, ICRP considers it appropriate to use the overall fatal risk coefficient of 5%/Sv, which serves as a basis of current international radiation safety standards, for radiation protection regulations, as provided in Publ. 103. Therefore, by carrying out back calculation using this overall fatal risk coef cient, the dose limit for members of the public, 1 mSv/y, is equivalent to a risk of approximately 5 10 -5 /y. To determine the significance of this risk of 5 10 -5 /y, it is effective to use an approach similar to the natural background radiationbased approach used to derive the dose limit for members of the public in Publ. 60. Moreover, understanding of existing background cancer risk is also important. The background risk due to spontaneously occuring cancers and heritable diseases includes all the risks associated with a possible risk arising from ingesting carcinogens and medical exposure. Therefore, knowledge of background cancer risk adjusted by detriment defined by ICRP is particularly important to examine the acceptability of an additional risk posed by exposure to a dose of 1 mSv/y or lower. However, background cancer risk has been used only for, for example, estimating mortalities of cancer and heritable diseases in the control group in epidemiological studies of populations exposed to low-dose radiation. That is, background cancer risk has been used as a baseline to detect excess cancer risk due to low-dose radiation exposure. There have been no studies in which background cancer risk has been evaluated as a detriment-adjusted risk de ned by ICRP.
In this study, the probability distribution of background cancer risk was examined, using the detriment-adjusted risk de ned by ICRP, on the basis of background cancer mortality data in Japan, to obtain information important in discussing the acceptability of radiation exposure in the low-dose region of 1 mSv/y or lower. Furthermore, the deviation of probability distribution of background cancer risk was evaluated and the obtained risk was compared with a) risks posed by exposure at 1 mSv/y, which is the dose limit for members of the public, b) assumed risk due to dose distribution of natural background radiation, and c) maximum assumed risk due to radiation from man-made radioactive nuclides, which may be caused by setting the dose constraint.
II METHODS

De nition of ICRP detriment
In ICRP Publ. 103, 2) nominal risk coef cients shown in the second column in Table 1 were assigned to various types of cancer (classified according to the affected tissue or organ, such as the oesophagus, stomach, colon, liver, lung, bone, skin, breast, ovary, bladder, thyroid, bone marrow (leukemia), other solid cancers, and gonad (heritable)) on the basis of epidemiological studies of survivors of the atomic bomb. Furthermore, nominal risk adjusted for lethality and quality of life (column 5) and relative cancer-free life lost (column 6), as well as detriment obtained by multiplying the former two parameters (column 7) are also shown in Table 1 . The detriment is calculated by
where T is the detriment for tissue or organ T (column 7), R T is the nominal risk coef cient for cancer incidence in tissue or organ T (column 2), k is the lethality fraction (column 4), q min is the minimum weight for nonlethal cancers (0.1, excluding skin; 0.0, for skin) and l T is the average life lost due to the disease relative to normal life expectancy. As shown in the last row in Table 1 , the total sum of detriments for these cancers and heritable diseases is de ned as detriment-adjusted risk in ICRP Publ. 103 and serves as the basis for the overall fatal risk coef cient of 5%/Sv. Relative detriment shown in column 8 is used for determining the tissue weighting factors used to calculate the effective dose.
Nominal risk coefficients (column 2 in Table 1 ) were calculated on the basis of data on mortality from cancer or heritable diseases given in Publ. 60 1) ; however, they were calculated on the basis of cancer incidence in Publ. 103, because incidence data provide a more complete description of the cancer burden than do mortality data, particularly for . On the basis of the above discussion, to examine background cancer risk using detriment-adjusted risks de ned by ICRP, the use of mortality data or cancer incidence data does not signi cantly affect results.
Data on background cancer mortality in Japan
The Center for Cancer Control and Information Services, National Cancer Center has been collecting cancer mortality data in Japan as necessary information to promote cancer control comprehensively and systematically. The two types of registry, i.e., 1) the hospital-based cancer registry available at cancer medical-examination hub hospitals and 2) populationbased cancer registry available at each prefecture, were standardized, collected, and calculated to obtain accurate statistical information on cancers. The cancer mortality of the group that includes many elderly patients is higher than that of the group that includes younger patients, because cancer mortality increases with age. Therefore, even if there is a difference in cancer mortality between the two groups, it is difficult to determine if the difference is due to the real difference in cancer mortality or to the difference in age distribution in the group. To solve this problem, when cancer mortality is compared between groups of different ages or when yearly changes in cancer mortality within the same group are examined, age-adjusted mortality is used. Age-adjusted mortality is calculated by adjusting the cancer mortality of the entire group to that of a group with an age distribution similar to that of a standard group (standard population). Here, a model population in 1985 (a virtual population distribution assumed on the basis of the population in Japan in 1985) is used as a standard population in Japan. In this study, age-adjusted mortality from malignant neoplasm for people aged less than 75 years depending on the affected tissue or organ for each prefecture in 2007 (hereafter, 2007 age-adjusted mortality data) provided by the Center for Cancer Control and Information Services, National Cancer Center was used as background cancer mortality in Japan.
III RESULTS
Probability distribution of detriment-adjusted risk
determined on the basis of background cancer mortality The 2007 age-adjusted mortality data were classi ed for the following 15 affected tissues and cancer types: 1) oesophagus (C15), 2) stomach (C16), 3) colon (C18), 4) rectosigmoid junction and rectum (C19-C20), 5) liver and intrahepatic bile ducts (C22), 6) gall bladder and unspecified parts of biliary tract (C23-C24), 7) pancreas (C25), 8) trachea, bronchus and lung (C33-C34), 9) breast (C50), 10) uterus (C53-C55), 11) ovary (C56), 12) prostate (C61), 13) malignant neoplasms in bladder (C67), 14) malignant lymphoma (C81-C85), and 15) leukemia (C91-C95), where the number in the parentheses shows the International Classi cation of Diseases (ICD) code. This classification is slightly different from that of ICRP shown in Table 1 . Therefore, a) for the data on the liver and intrahepatic bile duct, we used the data on the liver in ICRP; b) for the data on the trachea, bronchus and lung, the data on the lung in ICRP; c) for the data on malignant neoplasms in bladder, the data on the bladder in ICRP; d) for the data on leukemia, the data on bone marrow in ICRP; and e) for the data on rectosigmoid junction, gall bladder and biliary tract, pancreas, uterus, prostate gland and malignant lymphoma, the data on other solid cancers in ICRP. Furthermore, the data on bone, skin, thyroid, and gonads (heritable) were not included in the calculation of detriment-adjusted risk, because no corresponding data were found in the 2007 age-adjusted mortality data.
In accordance with the method described above, the 2007 age-adjusted mortality data were reclassified using the classification of ICRP. Detriment, as defined by ICRP and shown in Table 1 , was rst calculated for the affected tissue or organ by substituting the age-adjusted mortality data into kR T in Eq. (1), then detriment-adjusted risk by prefecture was calculated by adding up the detriments for all tissues or organs. Thus-obtained detriment-adjusted risks for 47 prefectures were weighted by the population of each prefecture to obtain the probability distribution (frequency distribution) of detrimentadjusted risk, i.e., population distribution of detriment-adjusted risk. The population estimates by prefecture, 5-year-age group, and gender as of 1 st Oct. 2007 provided by the Statistics Bureau of the Ministry of Internal Affairs and Communications were used as the data for populations in 47 prefectures. Figure 1 shows the probability plot of population distribution of detrimentadjusted risk in Japan. As shown in Fig. 1 , the plot of detrimentadjusted risk shows a linear increase, which indicates that the probability distribution of detriment-adjusted risk can be regarded as a normal distribution. It was found that the arithmetic mean detriment-adjusted risk determined on the basis of the background cancer mortality in Japan was 1.2 10 -3 /y and the detriment-adjusted risk corresponding to the standard deviation was 7.4 10 -5 /y. In the following section, the thus-obtained normal distribution is referred to as the distribution of background cancer risk.
IV DISCUSSION
Comparison between background cancer risk and
assumed risk due to natural background radiation The United Nations Scienti c Committee on the Effects of Atomic Radiation (UNSCEAR) 2000 Report showed that the global average annual dose due to natural background radiation is 2.4 mSv/y, and examples of annual dose distributions in 15 countries are presented.
3) The arithmetic mean dose distribution is approximately 2.0 mSv/y, 3) and the distribution has a peak in the dose region lower than the arithmetic mean and can be represented as a lognormal distribution. In this study, it is assumed that the distribution of dose due to natural background radiation has a lognormal distribution with a geometric mean of 2.0 mSv/y and a geometric standard deviation of 2.0.
4) The arithmetic mean of this distribution is theoretically 2.5 mSv/y, which fairly agrees with the value (2.4 mSv/y) reported by UNSCEAR. This finding indicates that our assumed distribution is reasonable.
Whether low-dose exposure actually poses cancer risks in living organisms has not yet been scienti cally proven. In this study, the distribution of dose due to natural background radiation was converted to the probability distribution of detriment-adjusted risk using the fatal risk coefficient, 5%/ Sv, reported in Publ. 103. Figure 2 shows a comparison between background cancer risk and assumed risk due to natural background radiation. The median of assumed risk due to natural background radiation is smaller by at least one order than the median of background cancer risk. There is no overlapping between the two distributions.
distribution of maximum assumed risk due to radiation from man-made radioactive nuclides There are few studies in which the distributions of external and internal doses that affect members of the public due to discharge of man-made radioactive nuclides have actually investigated. Thus, if any, no rationale can be found to consider a case study result as a representative dose distribution. However, there are some cases in which the dose distributions of radiation that workers in nuclear facilities were exposed to, where individual doses were not limited and controlled, were similar to the lognormal distribution, 5) which is the same as that in the case of natural background radiation. For this reason, the dose distribution of radiation due to a man-made source that members of the public may be exposed to was assumed to be lognormal in the present study.
Lognormal distributions are determined by two parameters, E GM (median, geometric mean) and S G (geometric standard deviation), which represent the degree of scattering. As described in the previous section, the S G of the dose distribution due to natural background radiation was assumed to be 2.0. From the point of view of external and internal exposures through various pathways, because both natural and discharged manmade nuclides are distributed in the environment by the same way, the dose distributions of radiations due to natural and man-made nuclides would be similar each other. For this reason, the S G of a dose distribution of radiation due to manmade nuclides was assumed to be 2.0, which is the same as due to natural background radiation.
On the other hand, the assumption of an appropriate E GM is closely related to the requirement for compliance with dose constraint using the concept of a representative person, which was published in Publication 101 by ICRP.
6) The representative person is a hypothetical person who receives a dose that is representative of the more highly exposed people in the population. In a probabilistic dose assessment, ICRP recommends that the representative person should be de ned such that the probability is less than about 5% that a person drawn at random from the population will receive a greater dose. This concept recommended by ICRP defines how the dose constraint should be complied with using a probabilistic approach, in addition to the previous approach of compliance with the dose constraint, namely, the deterministic approach, which is based on conservative and simple dose assessments. That is, the magnitude of the conservativeness of the dose assessment is mathematically and more accurately given by the concept of the representative person.
When using the concept of recommended by ICRP, it can be proven theoretically using the following equation that the 95 th percentile of the dose distribution for the representative person is always lower than the dose constraint.
where D is the dose constraint (mSv/y) and E 95 is 95 th percentile of the dose distribution for the representative person (mSv/y). In the case of a lognormal distribution, the 95 th percentile can be obtained from E GM and S G as, Assumed risk due to natural BG radiation Fig. 2 Comparison between background cancer risk and assumed risk due to natural background radiation.
If a value of 2.0 is given to S G , then Eq. (3) can be expressed as,
The distribution of dose due to radiation from manmade radioactive nuclides for members of the public was obtained when 1 mSv/y (the dose limit and the maximum dose constraint for members of the public) was assumed as the dose constraint for public, and the obtained results were converted to the probability distribution of detriment-adjusted risk using the fatal risk coef cient, 5%/Sv, reported in Publ. 103. Because the distribution was obtained on the basis of the representative person concept proposed by ICRP, we can say that the distribution is the maximum assumed risk distribution due to radiation from man-made radioactive nuclides. Figure 3 shows a comparison between background cancer risk and assumed maximum risk due to radiation from man-made radioactive nuclides. The risk of 7.4 10 -5 /y (detrimentadjusted risk corresponding to 1 of background cancer risk) is also shown in Fig. 3 . The median of the assumed maximum risk due to radiation from man-made radioactive nuclides is approximately two orders smaller than that of background cancer risk. The assumed maximum risk due to radiation from man-made radioactive nuclides has a distribution considerably smaller than 7.4 10 -5 /y. This guaranteed that the risk for members of the public is suf ciently small and lower than the risk that is within the deviation of the background cancer risk, if there is appropriate radiation protection compliance with the dose limit of 1 mSv/y.
V CONCLUSIONS
The deviation of the probability distribution of background cancer risk was revealed quantitatively by examining the probability distribution of the risk adjusted by detriment defined by ICRP using the 2007 age-adjusted mortality data in Japan. Moreover, the median assumed risk due to natural background radiation was found to be smaller than the median background cancer risk by at least one order. Furthermore, the probability distribution of background cancer risk adjusted by detriment and the distribution of maximum assumed risk due to radiation from man-made radioactive nuclides determined on the basis of the representative person concept proposed by ICRP were compared. The results revealed that the risk for members of the public is suf ciently small and lower than the risk that is within the deviation of the background cancer risk if there is appropriate radiation protection compliance with the dose limit of 1 mSv/y.
Our proposed new approach based on the background cancer risk follows the risk-based and the natural background radiation-based approaches that have been used by ICRP to determine the dose limit for workers and members of the public. We hope that our approach will be internationally used as a tool for establishing a new radiation protection system that is more scienti c and rational by incorporating revisions that consider the background cancer risk in each country. assumed maximum risk due to radiation from man-made radioactive nuclides.
